NNP
ONC

Nachman Norwood & Parrott’s BeOne Medicines Ltd ONC Stock Holding History

Nachman Norwood & Parrott’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-20
Closed -$6K – 1083
2020
Q3 		$6K Buy
+20
New +$4.7K ﹤0.01% 921

Other funds holding ONC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Nachman Norwood & Parrott's ONC Position: Q4 2020 in Review

Nachman Norwood & Parrott sold out of BeOne Medicines Ltd (ONC) in Q4 2020, closing a stake of 20 shares — an estimated $6K sold.

Nachman Norwood & Parrott first reported a position in ONC in Q3 2020 and held it in 1 quarter. The position peaked at $6K in Q3 2020. 247 funds tracked by Wall St. Rank hold ONC as of Q4 2020.

  • Nachman Norwood & Parrott reported no remaining BeOne Medicines Ltd position as of Q4 2020 after selling out during the quarter.
  • Nachman Norwood & Parrott sold 20 BeOne Medicines Ltd shares in Q4 2020, an estimated $6K.
  • Nachman Norwood & Parrott first reported a position in BeOne Medicines Ltd in Q3 2020 and held it in 1 quarter.
  • Nachman Norwood & Parrott's BeOne Medicines Ltd position peaked at $6K in Q3 2020.
  • 247 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q4 2020.

Based on Nachman Norwood & Parrott's 13F filing for Q4 2020, filed 19 Jan 2021.